Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading Life Science company specializing in healthcare services digitalization announces the opportunity for shareholders, media, and other stakeholders to ask company-related questions in connection with its year-end report. The report will be available to the public on February 19, 2021 at 08.30 (8:30 a.m.) CET. Questions will be answered by Chief Executive Officer Anders Segerström in a video presentation that will be published on the first of March, 2021 on iZafe's website under the heading Investor Relations.
Please send your questions to before 10:00 (10 a.m.) CET on February 22, 2021. You can also use an online form to send your questions. This form is available on iZafe Group's website, Investor Relations page.
Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B), a leading Life Science company focused on the digitalisation of medication handling, is announcing the completion of a pilot project with private care provider Attendo. The pilot project ran for two months in Attendo’s home care operations in Uppsala and Norrtälje. A phase of development of Dosell in close dialogue with Attendo is ongoing.
“Overall, the local authorities welcome digital medication dispensing. Patients who care deeply about being independent have taken Dosell as a miracle, as one happy customer in Norrtälje put it. Gathering suggestions for improvements that make it possible for Dosell to reach even more service users was a vital aspect of the project. A phase of testing and development of the new features is ongoing in consultation with Attendo, and we will maintain close dialogue with Attendo to help each other further,” says Anders Segerström, CEO, iZafe Group.
“We have carried out the project and see future potential in the product. Cooperation with iZafe Group went very well and it has been interesting to follow this project. Dosell has had positive effects on the medication management and for those customers who want to be independent, Dosell has been very well received.” says Susanne Åhlander, Assistant Regional Manager, Attendo.
The aim of the project was for the parties involved to answer the following questions:
Are there customer categories in the home care operations whom the product would help?
The product will help customer categories including people with cognitive decline or whose medications must be taken precisely on time, but who are otherwise independent. The Dosell medication dispensing robot improves medication handling. Dosell is a good alternative to quick visits to patients who live far away and allows service users to decide whether want more short visits or fewer, longer and more qualitative visits from home care staff.
There are advantages to not having to drive to all customers to deliver medication. There are also potential coordination gains to be had, in that visiting schedules for home care services are not controlled by the need to distribute medication.
Customers who want to be as independent as possible were highly receptive to the medication dispensing robot when they were introduced to Dosell. The customers who declined said that they did not want to lose the social interaction with home care staff.
Can the product be integrated into existing systems?
iZafe Group provided training of all lead nurses and participating members of staff in each home care operation. Attendo has also had access to support throughout the period. Attendo has suggested adjustments to reach a wider group of service users, which iZafe Group has added to the development plans for Dosell.
Can the product be used in a patient and medication-safe way?
A few features need further adjustment to achieve maximum reliability, but nurses perceive the risks as low. The local operations see no risks linked to use of Dosell by specific patient categories, as their is access to staff who can manage the device.
About Attendo AB Attendo AB is a listed Swedish company that offers services in elderly care, care for people with disabilities and individual and family care. The company also operates in Finland and Denmark.
In November 2019, iZafe Group AB (publ) (“iZafe” or “the Company”), a leading Life Science company forcused on the digitalisation of medication handling, completed a rights issue in the form of shares and free warrants. The exercise period for the series TO 8 B warrants ran from December 4, 2020 through December 18, 2020 and has thus ended. In total, 1,216,429 series TO 8 B warrants – which equals around 45 percent of the warrants – were exercised.
A total of 1,216,429 warrants were exercised, representing about 45 percent of all warrants, to subscribe for 1,216,429 Class B shares at an exercise price of SEK 3.30 per Class B share. The exercised warrants thus provide iZafe with proceeds of about SEK 4 million before issue costs.
Number of shares and share capital Exercise of the warrants increases the number of shares in iZafe by 1,216,429 Class B shares, from 32,262,081 to 33,478,510 shares. The share capital increases by about SEK 1,216,429 from about SEK 32,862,081 to about SEK 34,078,510.
The issue entails a dilution effect of the share capital of approximately 3.6 percent and of the number of votes of approximately 3.1 percent.
Advisor Stockholm Corporate Finance AB is acting as financial advisor, KANTER Advokatbyrå KB as legal advisor and Hagberg & Aneborn Fondkommission AB as issuing agency in connection with the exercise of the warrants.
About Stockholm Corporate Finance Stockholm Corporate Finance is an independent privately-owned financial advisor offering expert advisory services relating to capital raising, changes in ownership, and mergers, acquisitions and divestments (M&A) for listed and privately held companies and their owners. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which is comprised of 50 M&A advisors and investment banks in 35 countries. Stockholm Corporate Finance is under the supervision of Finansinspektionen (Sweden’s financial supervisory authority) and is a member of industry organization SwedSec Licensiering AB. For more information see www.stockholmcorp.se/eng/.
Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading life science company focused on the digitalization of medication management, is announcing that it already at an early stage has received in total 450 pre-orders of Dosell units from its partners before 2021. The orders are a result of the new features that have been developed during the past year. Production of the updated version of Dosell will begin during the first quarter of 2021 and deliveries will be carried out successively thereafter.
“We have established a broad partner network in Sweden, Norway, Finland, Italy and most recently in the United States. As previously communicated, we have developed Dosell to become even more user-friendly with the feedback of our partners and their customers. During the first quarter of 2021, production of the new updated version of Dosell will begin and we have thus at an early stage already received 450 pre-orders, which will be delivered in 2021 in pace with the production.” Says Anders Segerström, CEO of iZafe Group.
iZafe Group has in a short time built up increased capacity by establishing a partner network that successfully positioned Dosell as the leading product in drug dispensing. The company has won a number of business deals, signed agreements with new partners and successfully participated in a national procurement of medication dispensing robots in Norway. In addition, a number of pilot projects have been started and implemented with a good response from users and care providers.
“Despite the challenges we, our partners and their customers have faced due to the Covid-19 pandemic, we now see how decision-makers are ready to apply new technology. Our partners have built their organization and created the conditions for a broader sale of Dosell. As our partners note an increasing demand and have learned the product, they want to pre-order the updated version of Dosell at an early stage to be able to deliver quickly. In light of the business we are doing and the pilots that will start next year, we look very positively towards 2021.” Anders Segerström, CEO of iZafe Group, continues.
Stockholm, Sweden and Espoo, Finland – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading life science company focused on the digitalization of medication management, is announcing the launch of two pilot projects in two Finnish municipalities together with Vivago. In addition to these pilots Vivago will also participate with Dosell in a number of procurements in Finland during 2021.
In connection with iZafe Group's successful verification of Finnish sachets from Finland's largest pharmacy chain University Pharmacy, a broader pilot operation is now being launched in which these are the first two projects. During the autumn, major training initiatives were carried out to prepare for the launch in Finland and to successfully launch the pilot projects where users will try Dosell to ensure safe and compliant medication via sachets.
“The pilot projects in Finland are particularly interesting as Finland is a strategically important market for the iZafe Group as the digitizing of healthcare is making rapid progress there. 60,000 people are already managing their medication with sachets in Finland and these users represents future users of Dosell. This customer group is also expected to grow rapidly over the coming years.” comments Anders Segerström, CEO of iZafe Group.
The outcome of the pilot projects in the municipalities will form the basis for integrating medication via the dispensing of sachets and the digital medication-dispensing robot Dosell to increase safety and security for users and reduce the need for home visits for patients taking medication.
“We have identified the wide customer need for managing medication and ensure safety of the medication, and this is a great opportunity for us to build a co-operation in this field with iZafe Group and University Pharmacy. These first pilots represent the future offering of Vivago, and we are expecting expeditious growth from this market within next years.” Says Niina Vilkas, CEO of Vivago Ltd.
About University Pharmacy University Pharmacy is Finland’s largest pharmacy chain with 17 pharmacies and an online store ya.fi. It provides 10% of all prescription medicines to the general public in Finland. More than 1000 employees work for a healthier tomorrow. University Pharmacy is owned by Helsinki University and its turnover in 2019 was €355 million. All profit goes into Finnish research and education.
About Vivago Vivago develops smart safety and wellbeing solutions for preventive care by monitoring users’ health status and wellbeing in real-time, 24/7. The Vivago solution includes all features required for nurse call systems and covers the entire chain of care from home care and assisted living to rehabilitation centers and hospitals. More than 100,000 people use Vivago solutions every single day. Full digitalization of health status monitoring is opening a revolutionary path to changing care delivery from reactive to preventive while tailoring entirely patient-centered and results-driven care.
The exercise period for series TO 8 B warrants issued in connection with the rights issue of units by iZafe Group AB (publ) in November 2019 continues up to and including December 18, 2020. The last day of trading in series TO 8 B warrants on First North Premier Growth is today December 16, 2020. Each series TO 8 B warrant held entitles the holder to subscribe for one new Class B share in iZafe at a price of SEK 3,30 per Class B share. If all the series TO 8 B warrants are exercised, a total of 2,862,129 new Class B shares will be issued, and iZafe will receive proceeds of around SEK 9,4 million before transaction costs.
If your warrants are held by a nominee (in a custodian account like Nordnet or Avanza, an investment savings account (ISK) or endowment policy (KF), you must contact your nominee to subscribe.
If you wish to exercise warrants that are registered in your own name (held in a securities (VP) account), you need to download and complete a Notice of Exercise form (Sw. Anmälningssedel) that can be found at www.hagberganeborn.se or be downloaded directly here.
Note that series TO 8 B warrants will expire and become worthless if the holder does not actively subscribe for shares by December 18, 2020, or alternatively sell their warrants by December 16, 2020.
Advisor Stockholm Corporate Finance AB is acting as financial advisor, KANTER Advokatbyrå KB as legal advisor and Hagberg & Aneborn Fondkommission AB as issuing agent in connection with the exercise of the warrants.
About Stockholm Corporate Finance Stockholm Corporate Finance is a Swedish, independent and privately-owned financial advisor which offers financial advisory by taking transaction initiatives, acting in an advisory capacity and assisting with transaction process implementation, working closely with owners, board members and management in listed and privately held companies.
Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which is comprised of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is under the supervision of Finansinspektionen (Sweden’s financial supervisory authority) and is a member of industry organization SwedSec Licensiering AB. For more Information, see www.stockholmcorp.se /eng/.
Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B), a leading company focused on the digitalisation of medication handling, is announcing that it is entering into a collaborative partnership with Doro in Sweden as a direct result of the successful take-off with Doro in Norway.
“Thanks to the positive outcome of our partnership with Doro in Norway, we have now also partnered with Doro in Sweden to address the Swedish market. Doro Norway have been delighted with our stable technology and favourable pricing as a valuable complement to their social welfare technology platform,” remarks Anders Segerström, CEO, iZafe Group.
As previously communicated, iZafe Group has initiated a pilot project with Doro in Norway and begun deploying 50 Dosell medication dispensing robots in the homes of care recipients in one of the 30 municipalities in which Doro has implemented its social welfare platform. iZafe Group is today announcing that the partnership has been extended to include Doro in Sweden.
Doro enjoys a unique market position as a leading supplier of social alarms, remote monitoring and alarm reception services in the Swedish market. The partnership with Dosell enables Doro to further expand its offering in the same segment.
“Naturally, we at Doro could not be more pleased about the partnership with iZafe. iZafe is a company that is clearly compatible with our values-based approach and our vision of simplifying life and providing peace of mind to our seniors. Dosell is a state-of-the-art product that makes life easier for seniors and care workers alike. We are looking forward to working with iZafe and have high hopes that they will be able to help us make our current and future offering to our customers even better,” says Martin Puumalainen, Country Director Sweden Business Area Doro Care.
About Doro AB Doro is a tech company that focuses on seniors. We develop products and services for seniors to make ageing an independent, empowering and rich part of life. Our wide portfolio of products and services for security and care solutions help link generations digitally and create a secure and independent life at home and away from home. Doro is the market leader in social alarms in Sweden, Norway and the UK and the global market leader in smartphones for seniors. Doro is a Swedish company with headquarters in Malmö and sales operations in 27 countries. Shares in Doro are listed on Nasdaq Stockholm. The company had about 1,000 employees in 2019 and net sales of SEK 2,063 million (EUR 195.4 million). Read more about Doro at www.doro.se/corporate.
Stockholm, Sweden and Seattle, USA – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life Science company focused on the digitalization of medication management announced it has signed a partnership agreement with Hippo Technologies, Inc., a US based virtual care company, to co-develop a medication dispensing service based on iZafe Groups leading medical management robot Dosell.
iZafe Group and Hippo Technologies will develop a service based on the Dosell robot for customers worldwide using the Hippo Virtual Care platform and products. Dosell is meant for use by patients at home and it will automate dispensing of prescribed medication in dose-packed sachets. The intention is to extend the partnership to include an OEM-version of Dosell.
“Hippo enables virtual care worldwide and is pleased to add this vital function to improve quality of life and health for patients, and to lower the total cost of healthcare,” said Patrick Quinlan, M.D, CEO and co-founder of Hippo Technologies. ”It’s part of Hippo’s goal to make Polymorphic Medicine a reality – our approach to health and care is an optimal blend of self-care, physical care, and virtual care, matching patient needs and preferences with available resources to maximize outcomes.”
The goal with Dosell is to create a full-coverage solution for clinicians and patients while reducing the cost and need for daily home health visits in connection with taking medication. The partnership is an important step for iZafe Group's future investment in digitization of drug dispensing in Europe and the US while broadening Hippo's range of virtual care products and services.
"I am thrilled to get an opportunity to collaborate with one of the leading and most innovative virtual care company to use advances in robotics to solve a significant challenge in healthcare and patient health." comments Anders Segerström, CEO of iZafe Group. “Our work with Hippo Technologies will help close the gap between physical care and virtual care, ultimately improving the delivery of health care.”
About Hippo Technologies, Inc. Hippo Technologies, Inc., is a global team of healthcare professionals, technologists, experience designers and innovators. Its mission is to serve patients and those who care for them by leading the transformation to virtual care for providers and educators, expanding access to clinical expertise and technologies to improve the quality of healthcare. For more information please visit Hippo Technologies, Inc., or connect with Hippo Technologies on Twitter and LinkedIn.
Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B), a leading Life Science company focused on the digitalisation of medication handling, is announcing that it will begin delivering a consumer version of Dosell in spring 2021. With the launch, iZafe Group is creating an entirely new consumer market made up of about 200,000 people who already take their medicines using dose-packed sachets and those who keep track of their medications manually using dosette boxes, for example.
The consumer version of Dosell is a subscription service that will be the only medication dispensing robot in Sweden that offers the more than 200,000 people in Sweden who receive their medications in dose-packed sachets the opportunity to subscribe to a medication dispensing robot with no need for the health or home care system to provide the equipment.
iZafe Group is strengthening its position as the leading developer of digital medication dispensing in the home by offering the first consumer version of the most convenient, safe and economical medication dispensing robot on the market to hundreds of thousands of patients, families and home health care personnel.
“For some time, we have been observing the ground-breaking work of our Italian partners to establish Sempli Farma, a service offered via pharmacies that connects treating physicians with patients and their families through a closed medication dispensing system. Dosell is a key strategic component of Sempli Farma and the time has now come for us to take the initiative and establish a similar system. The Dosell Konsument (Dosell Consumer) service will initially be launched in the Swedish market,” says Anders Segerström, CEO of iZafe Group. “We have invested during the year in product development and upgrading of Dosell and the software to adapt Dosell and the Dosell app to the consumer market, which will also be of tremendous benefit to other customers and users.”
Read more about the forthcoming launch of Dosell Consumer and pre-register for the service here.
Dosell Consumer is one component of the long-term strategy to position iZafe Group as a key player in the digitalisation of home health care. DosPac* from Apoteket AB and MinDos** from Kronans Apotek, for example, have already made it possible for anyone to get their medicines in dose-packed sachets, regardless of whether or not a doctor has prescribed the service. These services, for which the patient pays a small monthly fee, allow the patient and their relatives to decide the safest way to handle their medications.
Dosell Consumer is aimed primarily at the more than 200,000 people who already receive their medications in dose-packed sachets, as well as all of those who choose in the future to pay for medication delivered in sachets via DosPac and MinDos to enhance safety and peace of mind. Dosell Consumer will also appeal to relatives who want to make sure their loved ones take the right medicines at the right time to improve wellbeing and minimise the risk of medication errors. If the person does not take their medication as planned, the Dosell app notifies a relative or care professional, who can act quickly to make sure the medication is taken as prescribed.
Dosell Consumer will provide secure and valuable assistance to people who want to make medication handling safer while giving them more freedom and independence. This will be particularly valuable for older people and those who take multiple medications, for example. Safe and secure medication dispensing increases independence and helps make it possible for people to remain in their own homes longer.
“Dosell substantially improves patient safety because it prevents the user from taking the wrong medicine or missing a dose. We believe this will be hugely appreciated by people who want to offer the service to their parents and other relatives. Users will no longer have to arrange their days around home care visits and can live their lives more freely,” concludes Anders Segerström, CEO of iZafe Group.
In pace with the digitalisation of health care, iZafe Group is setting a new standard for digital dose-packed dispensing in the home that is making digital medication dispensing available to everyone who wants to create a safe and secure setting for medication dispensing.
With products like Dosell Consumer and future patents, iZafe Group is poised to revolutionise at-home care, especially for users who want to live independently at home for longer, but with the peace of mind that comes with knowing relatives and care professionals can step in if something goes wrong.
About Dosell Consumer
Dosell Consumer and the Dosell app are a niched version of iZafe’s professional solution, adapted so that that users and relatives can administer and ensure the right medication themselves, without being dependent on care professionals.
Alarms can be sent to up to three recipients. The associated app has been adapted and gives the user control over settings including the following:
The exact time that medicine can be taken and whether it can be dispensed before the scheduled time. Dispensing earlier than prescribed should always be approved by the treating physician before the intake time is changed.
Administration of the individuals who will be recipients of alarm events.
When and how alarms are sent via SMS to recipients with a warning that scheduled medicine has not been taken out of Dosell.
Dosell Consumer has a dedicated app with a simpler, adapted design for consumer use. The app is compatible with all smart phones and can be downloaded from Google Play and the Apple App Store.
Dosell Consumer will be available from sources including pharmacies, local medical centres and partners, as well as via www.dosell.com.
Dosell Consumer is a subscription service.
Others, such as relatives, can sign up and pay for the Dosell Consumer subscription on behalf of the user.
As previously communicated, iZafe Group has a patent pending, which provides important protection for the company’s further development of Dosell as a digital platform. Dosell Consumer is yet another strategic step towards achieving the vision of “The digital ward in the home”.
Dosell Consumer will be available for delivery in the second quarter of 2021, but interested consumers can already sign up to ensure access when Dosell Consumer is launched.
Read more about the forthcoming launch of Dosell Consumer and pre-register for the service here.
Do you work in health care or home care? If you who work in health care or other professional home service provision and would like to know more about how you can work with and offer Dosell in your organisation, please contact:
Tobias Johansson Sales Manager iZafe Group AB (publ) +46 72-567 73 61
About dose-packed sachets from Apoteket AB and Kronans Apotek
*DosPac Do you or a relative take one or more medications, perhaps at different times of the day? With Apoteket DosPac, you will receive them pre-sorted, in the correct doses and pre-packed in daily dose-packed sachets, so you no longer have to take the time to do that. Each sachet contains the medications you are supposed to take at the same time. Your personal details, the contents of the sachet and when the medication is to be taken are printed on every sachet. That gives you control over making sure you take the right dose at the right time. Source: https://www.apoteket.se/dospac/
**MinDos MinDos is a subscription service for dose-packaging of your medications. Instead of receiving your medications in bottles or blister packs, you receive them pre-packed in a roll of individual dose-packed sachets. Each sachet contains all the medications you are supposed to take at the same time. Your personal details, the contents of the sachet and the time each medication should be taken are printed on the sachet. Source: https://www.kronansapotek.se/tjanster/mindos/
Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B), a leading life science company in the digitalisation of medication management, has announced that its CEO, deputy CEO and board members intend to utilise their options from series TO 8 B to subscribe for shares. During November 2019, iZafe carried out a rights issue of units including TO 8 B shares and options. The subscription period for TO 8 B is in progress and ends on 18 December 2020. The subscription price has been set at SEK 3.30 per B share. The intention to subscribe equates to an issue of 113,471 shares in total.
“During this year, iZafe Group has assumed a position as a leading player in the market for digital medication management. As a pure life science company with our medication dispensing robot Dosell we have made huge progress, and we are continuing to develop the business at a rapid pace. The capital contribution from the subscription to shares in TO 8 B will create further conditions for the commercialisation and widespread introduction of Dosell in the Nordic countries and in Italy,” commented Anders Segerström, CEO of iZafe Group.
The declarations of intent have not been secured via advance transaction, bank guarantee or similar.
Advisors Stockholm Corporate Finance AB is the financial advisor, KANTER Advokatbyrå KB is the legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing body connected to the option redemption.
About Stockholm Corporate Finance Stockholm Corporate Finance is an independent, privately owned financial consultancy offering qualified consultancy services relating to capital procurement, changes of ownership, acquisitions, mergers and disposals (M&A) to listed and private companies and their owners. Stockholm Corporate Finance is an exclusive Swedish partner in the global network M&A Worldwide, which is made up of 46 M&A consultants and investment bankers in 38 countries. Stockholm Corporate Finance is a securities company regulated by the Swedish Financial Supervisory Authority and is a member of the sector organisation SwedSec Licensiering AB.
